nafamostat has been researched along with Sepsis in 4 studies
nafamostat: inhibitor of trypsin, plasmin, pancreatic kallikrein, plasma kallikrein & thrombin; strongly inhibits esterolytic activities of C1r & C1 esterase complement-mediated hemolysis; antineoplastic
Sepsis: Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.
| Excerpt | Relevance | Reference |
|---|---|---|
| " We analyzed therapeutic advantage of nafamostat, a broad-range protease inhibitor, on fibrinolysis in an animal sepsis model." | 7.73 | Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1. ( Hryszko, T; Ihara, H; Inaba, K; Mogami, H; Suzuki, Y; Urano, T, 2006) |
| " We analyzed therapeutic advantage of nafamostat, a broad-range protease inhibitor, on fibrinolysis in an animal sepsis model." | 3.73 | Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1. ( Hryszko, T; Ihara, H; Inaba, K; Mogami, H; Suzuki, Y; Urano, T, 2006) |
| "Nafamostat mesilate (NM), a synthetic protease inhibitor, is frequently used for the treatment of disseminated intravascular coagulation (DIC) in Japan." | 3.69 | Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity. ( Abe, H; Okabe, H; Okajima, K; Takatsuki, K; Uchiba, M, 1994) |
| "Whereas in DIC associated with trauma, since balance between coagulation and fibrinolysis collapses drastically in a short period, both anticoagulantion therapy and antifibrinolytic therapy can be utilized depending on clinical conditions." | 2.53 | [Anti DIC therapy]. ( Sakamoto, Y; Yahata, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (25.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yahata, M | 1 |
| Sakamoto, Y | 1 |
| Sawaki, D | 1 |
| Otani, Y | 1 |
| Kobayakawa, N | 1 |
| Sekita, G | 1 |
| Fukushima, K | 1 |
| Takeuchi, H | 1 |
| Ogawa, T | 1 |
| Takemura, T | 1 |
| Aoyagi, T | 1 |
| Hryszko, T | 1 |
| Inaba, K | 1 |
| Ihara, H | 1 |
| Suzuki, Y | 1 |
| Mogami, H | 1 |
| Urano, T | 1 |
| Uchiba, M | 1 |
| Okajima, K | 1 |
| Abe, H | 1 |
| Okabe, H | 1 |
| Takatsuki, K | 1 |
1 review available for nafamostat and Sepsis
| Article | Year |
|---|---|
[Anti DIC therapy].
Topics: Anticoagulants; Antifibrinolytic Agents; Antithrombins; Benzamidines; Disseminated Intravascular Coa | 2016 |
3 other studies available for nafamostat and Sepsis
| Article | Year |
|---|---|
A case of heparin-induced thrombocytopenia with sepsis and congestive heart failure--first autopsy report on Japan--.
Topics: Aged; Aged, 80 and over; Antibodies; Benzamidines; Enzyme-Linked Immunosorbent Assay; Fatal Outcome; | 2004 |
Nafamostat attenuated the impairment of fibrinolysis in animal sepsis model by suppressing the increase of plasminogen activator inhibitor type 1.
Topics: Animals; Benzamidines; Drug Interactions; Fibrinogen; Fibrinolysis; Guanidines; Interleukin-10; Lipo | 2006 |
Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity.
Topics: Amino Acid Sequence; Benzamidines; Blood Coagulation; Disseminated Intravascular Coagulation; Factor | 1994 |